Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 209

1.

Pharmacokinetics of pegylated liposomal doxorubicin administered by intraoperative hyperthermic intraperitoneal chemotherapy to patients with advanced ovarian cancer and peritoneal carcinomatosis.

Salvatorelli E, De Tursi M, Menna P, Carella C, Massari R, Colasante A, Iacobelli S, Minotti G.

Drug Metab Dispos. 2012 Dec;40(12):2365-73. doi: 10.1124/dmd.112.047480. Epub 2012 Sep 12.

2.
3.

Peritonectomy and hyperthermic chemotherapy in patients with advanced or recurrent ephitelial ovarian cancer: a single center cohort study.

Massari R, Barone M, Basilico R, Carella C, Colasante A, De Tursi M, Filippone A, Guetti L, Mani A.

Minerva Chir. 2014 Feb;69(1):17-26.

PMID:
24675243
4.

Treatment of peritoneal carcinomatosis from ovarian cancer by surgical cytoreduction and hyperthermic intraperitoneal chemotherapy (HIPEC).

Robella M, Vaira M, Marsanic P, Mellano A, Borsano A, Cinquegrana A, Sottile A, De Simone M.

Minerva Chir. 2014 Feb;69(1):27-35.

PMID:
24675244
5.

Peritonectomy and hyperthermic intraperitoneal chemotherapy (HIPEC) for ovarian peritoneal carcinomatosis: an argued role.

Di Giorgio A, Cardi M, Sammartino P.

Gynecol Oncol. 2010 Apr;117(1):146-7. doi: 10.1016/j.ygyno.2009.12.026. Epub 2010 Jan 22. No abstract available.

PMID:
20096922
6.

Extent of parietal peritonectomy does not change intraperitoneal chemotherapy pharmacokinetics.

de Lima Vazquez V, Stuart OA, Mohamed F, Sugarbaker PH.

Cancer Chemother Pharmacol. 2003 Aug;52(2):108-12. Epub 2003 May 21.

PMID:
12759776
7.

Perioperative fast track program in intraoperative hyperthermic intraperitoneal chemotherapy (HIPEC) after cytoreductive surgery in advanced ovarian cancer.

Cascales Campos PA, Gil Martínez J, Galindo Fernández PJ, Gil Gómez E, Martínez Frutos IM, Parrilla Paricio P.

Eur J Surg Oncol. 2011 Jun;37(6):543-8. doi: 10.1016/j.ejso.2011.03.134. Epub 2011 Apr 13.

PMID:
21489742
8.

Pharmacokinetics of concomitant cisplatin and paclitaxel administered by hyperthermic intraperitoneal chemotherapy to patients with peritoneal carcinomatosis from epithelial ovarian cancer.

Ansaloni L, Coccolini F, Morosi L, Ballerini A, Ceresoli M, Grosso G, Bertoli P, Busci LM, Lotti M, Cambria F, Pisano M, Rossetti D, Frigerio L, D'Incalci M, Zucchetti M.

Br J Cancer. 2015 Jan 20;112(2):306-12. doi: 10.1038/bjc.2014.602. Epub 2014 Dec 2.

9.

Pharmacokinetics of cisplatin in semi-closed hyperthermic peritoneal perfusion (HPP) for treatment of peritoneal carcinomatosis.

Cattel L, De Simone M, Passera R, Verlengo MC, Delprino L.

Anticancer Res. 2004 May-Jun;24(3b):2041-5.

10.

[Importance of hyperthermic intraperitoneal chemotherapy (HIPEC) in ovarian cancer].

Ferron G, Martinez A, Mery E, Querleu D, Thomas F, Chatelut E, Gladieff L.

Bull Cancer. 2009 Dec;96(12):1243-52. doi: 10.1684/bdc.2009.1005. Review. French.

11.

Cytoreductive surgery (peritonectomy procedures) combined with hyperthermic intraperitoneal chemotherapy (HIPEC) in the treatment of diffuse peritoneal carcinomatosis from ovarian cancer.

Di Giorgio A, Naticchioni E, Biacchi D, Sibio S, Accarpio F, Rocco M, Tarquini S, Di Seri M, Ciardi A, Montruccoli D, Sammartino P.

Cancer. 2008 Jul 15;113(2):315-25. doi: 10.1002/cncr.23553.

12.

Evaluation of extensive cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC) in patients with advanced epithelial ovarian cancer.

Ansaloni L, Agnoletti V, Amadori A, Catena F, Cavaliere D, Coccolini F, De Iaco P, Di Battista M, Framarini M, Gazzotti F, Ghermandi C, Kopf B, Saponara M, Tauceri F, Vallicelli C, Verdecchia GM, Pinna AD.

Int J Gynecol Cancer. 2012 Jun;22(5):778-85. doi: 10.1097/IGC.0b013e31824d836c.

PMID:
22572845
13.

Safety and potential benefit of hyperthermic intraperitoneal chemotherapy (HIPEC) in peritoneal carcinomatosis from primary or recurrent ovarian cancer.

Roviello F, Pinto E, Corso G, Pedrazzani C, Caruso S, Filippeschi M, Petrioli R, Marsili S, Mazzei MA, Marrelli D.

J Surg Oncol. 2010 Nov 1;102(6):663-70. doi: 10.1002/jso.21682.

PMID:
20721959
14.

Treatment of peritoneal carcinomatosis from colonic cancer by cytoreduction, peritonectomy and hyperthermic intraperitoneal chemotherapy (HIPEC). Experience of ten years.

Vaira M, Cioppa T, D'Amico S, de Marco G, D'Alessandro M, Fiorentini G, De Simone M.

In Vivo. 2010 Jan-Feb;24(1):79-84.

PMID:
20133981
15.

Hyperthermic intraoperative intraperitoneal chemotherapy with cisplatin and doxorubicin in patients who undergo cytoreductive surgery for peritoneal carcinomatosis and sarcomatosis: phase I study.

Rossi CR, Foletto M, Mocellin S, Pilati P, De SM, Deraco M, Cavaliere F, Palatini P, Guasti F, Scalerta R, Lise M.

Cancer. 2002 Jan 15;94(2):492-9.

16.

Cytoreductive surgery with hyperthermic intraperitoneal chemotherapy for the treatment of endometrial cancer with peritoneal carcinomatosis.

Delotte J, Desantis M, Frigenza M, Quaranta D, Bongain A, Benchimol D, Bereder JM.

Eur J Obstet Gynecol Reprod Biol. 2014 Jan;172:111-4. doi: 10.1016/j.ejogrb.2013.10.026. Epub 2013 Nov 5.

PMID:
24300558
17.

Impact of surgical and clinical factors on the pharmacology of intraperitoneal doxorubicin in 145 patients with peritoneal carcinomatosis.

Sugarbaker PH, Van der Speeten K, Anthony Stuart O, Chang D.

Eur J Surg Oncol. 2011 Aug;37(8):719-26. doi: 10.1016/j.ejso.2011.04.007. Epub 2011 May 31.

PMID:
21621952
18.

The role of hyperthermic intraoperative intraperitoneal chemotherapy (HIPEC) in the treatment of peritoneal carcinomatosis in recurrent ovarian cancer.

Muñoz-Casares FC, Rufián S, Rubio MJ, Díaz CJ, Díaz R, Casado A, Arjona A, Muñoz-Villanueva MC, Muntané J.

Clin Transl Oncol. 2009 Nov;11(11):753-9.

PMID:
19917539
19.

[Cytoreductive surgery and intraperitoneal hyperthermic-antiblastic therapy (HAPP) in peritoneal carcinomatosis].

Vaira M, Scuderi S, Costamagna D, Barone R, Aghemo B, Mioli PR, De Simone M.

Minerva Chir. 2002 Oct;57(5):597-605. Review. Italian.

PMID:
12370661
20.

[Intraoperative intraperitoneal chemoperfusion treatment with cisplatin and dioxadet on a model of peritoneal carcinomatosis in ovarian cancer: safety and efficacy evaluation].

Bespalov VG, Kireeva GS, Belyaeva OA, Senchik KY, Stukov AN, Gafton GI, Soloviev LA, Vasilchenko MV, Guseinov KD, Alexeev VV, Belyaev AM.

Vopr Onkol. 2015;61(4):647-52. Russian.

PMID:
26571838

Supplemental Content

Support Center